Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.41 |
| ▸ | SFRP1 | Q8N474 | 4/20 | 0.41 |
| ▸ | WNT3 | P56703 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10167002 | 0.83 | ESR1 (0.42) | SMN1; SMN2ALDH1A1POLBMAPTHSD11B1 | |
| SCHEMBL16481025 | 0.80 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1POLBMAPTSFRP1 | |
| SCHEMBL20246832 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1PTK2PTK2B | |
| SCHEMBL27841266 | 0.76 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1POLBMAPTHSD11B1 | |
| SCHEMBL8016610 | 0.75 | CYP19A1 (0.50) | ALDH1A1POLBCYP19A1 | |
| SCHEMBL4201103 | 0.74 | HTR6 (0.48) | SMN1; SMN2ALDH1A1POLBMAPTHSD11B1 | |
| SCHEMBL11226587 | 0.74 | CHRM2 (0.40) | SMN1; SMN2ALDH1A1POLBMAPTSFRP1 | |
| SCHEMBL10167001 | 0.72 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1POLBMAPTHSD11B1 | |
| SCHEMBL10262196 | 0.71 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1POLBMAPTHSD11B1 | |
| SCHEMBL4616057 | 0.70 | SFRP1 (0.48) | SMN1; SMN2ALDH1A1POLBMAPTHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| WO-2012056319-A1 | SULFONAMIDES FOR THE MODULATION OF PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | PDK1, PDK4, PDK2 | SMN1; SMN2 3384/4885ALDH1A1 2275/4885POLB 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.